Ep. 690: One Size Fits None: The Future of Precision Medicine

Episode summary: In this episode, Herman Poppleberry and Corn tackle the frustrating reality of "one size fits all" medicine in an era of hyper-personalization. Despite our ability to map genomes in hours, most prescriptions are still calibrated for a demographic that represents only a fraction of the population. The duo explores the biological mechanics of the liver's cytochrome P450 system and why genetic variations mean a standard dose can be toxic for one person and useless for another. They delve into the economic and regulatory reasons why the "Blockbuster Model" of mass-produced pills persists and how 3D printing and "model-based" regulation are finally paving the way for precision dosing. From the challenges of compounding pharmacies to the futuristic concept of "digital twins" for physiological simulations, this conversation explores how we are moving toward a world where your medication is as unique as your DNA. Join the hosts as they navigate the intersection of biology, economics, and law to uncover the next frontier of human health.

Show Notes

In a recent episode, hosts Herman Poppleberry and Corn explored a glaring contradiction in modern society: while almost every aspect of our lives—from our social media feeds to our custom-fit running shoes—is hyper-personalized, the medical field remains stubbornly tethered to an industrial-age, "one size fits all" philosophy. Corn opened the discussion with a striking metaphor, comparing the human body to a unique architectural structure. If every person is built with different blueprints and electrical systems, why does the medical system attempt to repair every "building" with the same size screwdriver and the same bucket of gray paint?

### The Myth of the Average Patient The conversation quickly centered on the "bell curve" problem in pharmacology. Herman explained that for decades, drug regulation and clinical trials have been built around the concept of the "average patient." Historically, this average was modeled after a seventy-kilogram white male, a demographic that represents only a small sliver of the global population.

This reliance on averages creates what Herman calls the "paradox of the bell curve." When a drug is tested, researchers look for the "Goldilocks dose"—a dosage high enough to be effective for the majority but low enough to avoid poisoning them. However, this leaves the individuals on the edges of the curve—the "outliers"—in a precarious position. For these patients, a standard dose might be completely ineffective or, conversely, dangerously toxic.

### The Biology of Variability: The CYP System To explain why individuals react so differently to the same chemical, Herman pointed to the liver, specifically the cytochrome P450 (CYP) enzyme system. These enzymes act as the body's "chemical mechanics," breaking down foreign substances, or xenobiotics, so they can be excreted.

The hosts discussed how genetic variations dictate the efficiency of these enzymes. Herman highlighted the enzyme CYP2D6, which processes roughly 25% of all clinically used drugs. In the population, individuals fall into four metabolic categories: poor, intermediate, normal, and ultra-rapid metabolizers.

For a "poor metabolizer," a standard dose of a drug can build up in the system like water in a clogged sink, leading to toxicity. On the other end of the spectrum, "ultra-rapid metabolizers" process drugs so quickly that the medication never reaches a therapeutic threshold. This often leads to patients being labeled as "non-compliant" or drugs being dismissed as "ineffective," when the real issue is a simple mechanical mismatch between the dose and the patient's metabolic speed.

### The Regulatory and Economic Hurdles If the science of pharmacogenomics exists, why isn't every prescription tailored to a patient's DNA? Herman and Corn identified two primary barriers: regulation and manufacturing economics.

The current regulatory framework, governed by bodies like the FDA, relies on Randomized Controlled Trials (RCTs). To achieve statistical certainty, these trials require standardized variables. If every patient in a trial received a custom dose, the resulting "noise" in the data would make it nearly impossible to achieve the "p-value" required for drug approval.

Economically, the pharmaceutical industry is built on the "Blockbuster Model." It is incredibly cost-effective to manufacture ten million identical tablets. Moving toward custom dosages—such as a 27.3-milligram pill—would require a return to an apothecary-style model, which is difficult to scale and even harder to regulate for quality control.

### The Rise of 3D Printing and Digital Twins Despite these hurdles, the hosts noted that the landscape is shifting. As of 2026, the industry is moving toward "Continuous Manufacturing" and "Point-of-Care Manufacturing." Herman described a future where 3D printers in local pharmacies—or even homes—could print pills on demand using "ink" cartridges of active ingredients. This would allow for "poly-pills," where multiple medications are combined into a single tablet with customized release rates tailored to the individual.

Perhaps the most revolutionary concept discussed was the use of "digital twins." By creating a complex computer simulation of a patient's unique physiology—incorporating their genetics, age, kidney function, and even gut microbiome—doctors can run "flight simulations" for medication. Instead of trial and error on a living patient, physicians can test thousands of dosage variations in a virtual environment to find the "sweet spot" before the patient takes a single milligram.

### The Path Forward: Model-Based Regulation Herman explained that the FDA is already beginning to embrace "model-based" regulation. Rather than testing every physical iteration of a drug, regulators are looking at validating the algorithms that determine the dose. This shift represents a move from testing the product to testing the system that creates the product.

As the episode concluded, Corn raised concerns about equity, questioning whether precision medicine would become a luxury for the wealthy while the rest of the world remains stuck with "average" medicine. While the cost of technology like genome sequencing has plummeted, the challenge remains to ensure that these advancements in "Precision Dosing" are accessible to all. The transition from industrial-era medicine to the era of the individual is no longer a matter of "if," but "how" we navigate the ethical and economic complexities of a world where one size truly fits none.

Listen online: https://myweirdprompts.com/episode/future-of-precision-medicine